Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > U-M Nanotechnology Institute collaborates in $6 million vaccine program

Abstract:
U-M scientists tapped to help NanoBio Corporation develop Respiratory Syncytial Virus (RSV) intranasal vaccine

U-M Nanotechnology Institute collaborates in $6 million vaccine program

Ann Arbor, MI | Posted on December 3rd, 2010

The University of Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) will be collaborating with a U-M spinout company to develop a safe and effective Respiratory Syncytial Virus (RSV) intranasal vaccine.

Approximately one-third of a nearly $6 million grant awarded to the Ann Arbor-based NanoBio Corporation by the Bill & Melinda Gates Foundation will be subcontracted to MNIMBS in exchange for a two-year commitment to the project to help characterize the mechanism of action and in vivo immunogenicity of a series of nanoemulsion adjuvants and nanoemulsion-RSV vaccines.

Respiratory syncytial virus (RSV) is highly contagious and causes infection of the lungs and breathing passages. While symptoms are mild in adults, it is a major cause of respiratory illness in young children and can, in rare cases, cause death in infants, especially in developing countries. Children may develop chronic pulmonary disease and/or asthma that persists throughout adult life, making them susceptible to re-infection as adults. Currently, there are no approved vaccines for RSV.

"While originally developed as microbicidal agents at the MNIMBS, studies fortuitously demonstrated that nanoemulsions are a promising new type of adjuvant for nasopharyngeal vaccines. A needle-free, intranasally administered nanoemulsion-based RSV vaccine would be a great advance in the effort to prevent RSV infection," says James R. Baker, Jr., M.D., director of the MNIMBS and Ruth Dow Doan Professor of Internal Medicine at U-M. He also is founder and CEO of NanoBio.

MNIMBS invented the vaccine technology, and this technology was then transferred to NanoBio Corp. who named it NanoStat.™ The company's lead vaccine candidate, NB-1008, is a seasonal influenza vaccine administered via a nasal dropper. In a recently completed Phase 1 clinical study, NB-1008 was safe, well tolerated and elicited both mucosal and systemic immune responses following a single intranasal vaccination in a study of 199 healthy adults.

Other intranasal vaccines under development in animals by the MNIMBS and NanoBio Corp. include pandemic influenza, hepatitis B, HIV, pneumococcal, anthrax and smallpox. This platform technology has demonstrated numerous advantages over traditional vaccines, including the ability to generate robust mucosal and systemic immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles and refrigeration.

####

About University of Michigan Nanotechnology Institute for Medicine and Biological Sciences
The Michigan Nanotechnology Institute for Medicine and Biological Sciences is a true multidisciplinary team of chemists, physicists, engineers, toxicologists, physicians, biologists, pharmacists, and (bio)informatics specialists collaborating on nanoscience in biology and medicine. The MNIMBS first developed the nanoemulsion-based NanoStat™ technology that is further commercialized by NanoBio Corp.

About NanoBio
NanoBio Corporation, a University of Michigan spinoff, is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are nanoemulsion based treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Disclosures: Baker holds an equity interest in the NanoBio Corporation.

For more information, please click here

Copyright © University of Michigan

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Academic/Education

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

The Ottawa Hospital Research Institute uses the ZetaView from Particle Metrix to study membrane microparticles as potential biomarkers for underlying diseases April 12th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

SUNY Poly, in Collaboration with the George Washington School of Medicine and Health Sciences and Stony Brook University, Demonstrates Pioneering Method to Visualize and Identify Engineered Nanoparticles in Tissue March 25th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Brookhaven's Oleg Gang Named a Battelle 'Inventor of the Year': Recognized for work using DNA to guide and regulate the self-assembly of nanoparticles into clusters and arrays with controllable properties April 25th, 2016

Zip software can detect the quantum-classical boundary: Compression of experimental data reveals the presence of quantum correlations April 21st, 2016

Making electronics out of coal: Instead of burning up this complex hydrocarbon, let's make devices from it April 20th, 2016

Nano-magnets produce 3-dimensional images: Wide-view 3-dimensional holographic display composed of nano-magnetic pixels April 20th, 2016

Nanobiotechnology

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016

Leti Extends Collaboration with Qualcomm on CoolCubeTM 3D Integration Technology for High-Density, High-Performance ICs: Collaboration Goals Include Building an Ecosystem To Take the Chip-stacking Technology from Design to Fabrication April 13th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

Strem Chemicals and SONA Nanotech Sign Distribution Agreement for the World’s First Gold Nanorods Synthesized without CTAB February 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic